VYNE Therapeutics (VYNE) Short-term Investments (2016 - 2026)
VYNE Therapeutics (VYNE) posted Short-term Investments of $297000.0 for Q1 2026, down 94.04% on a QoQ basis from $5.0 million in Q4 2025, and down 98.65% year-over-year from $22.1 million in Q1 2025.
VYNE Therapeutics (VYNE) Short-term Investments (2016 - 2026) Analysis & Trends
VYNE Therapeutics' Short-term Investments history runs 10 years deep, the most recent figure standing at $297000.0 for Q1 2026.
- Quarterly Short-term Investments fell 98.65% year-over-year to $297000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $297000.0 (down 98.65% YoY) and the FY2025 annual result came in at $5.0 million, down 88.02% from the prior year.
- Short-term Investments was $297000.0 for Q1 2026 at VYNE Therapeutics, down from $5.0 million in the prior quarter.
- Across five years, Short-term Investments topped out at $66.9 million in Q1 2024 and bottomed at $297000.0 in Q1 2026.
- A 4-year average of $35.4 million and a median of $41.6 million in 2024 frame the typical range for Short-term Investments.
- Annual changes were most pronounced in 2024 — Short-term Investments tumbled 33.6% — and 2026, when it tumbled 98.65%.
- VYNE Therapeutics' Short-term Investments stood at $62.6 million in 2023, then plunged by 33.6% to $41.6 million in 2024, then sank by 88.02% to $5.0 million in 2025, then tumbled by 94.04% to $297000.0 in 2026.
- Business Quant data shows VYNE's Short-term Investments at $297000.0 in Q1 2026, $5.0 million in Q4 2025, and $17.6 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | VYNE Therapeutics | 1.19 Bn | 1.16 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 297,000.00 |
| Dec 31, 2025 | 4.98 Mn |
| Jun 30, 2025 | 17.60 Mn |
| Mar 31, 2025 | 22.06 Mn |
| Dec 31, 2024 | 41.59 Mn |
| Sep 30, 2024 | 53.91 Mn |
| Jun 30, 2024 | 48.49 Mn |
| Mar 31, 2024 | 66.89 Mn |
| Dec 31, 2023 | 62.63 Mn |
| Mar 31, 2021 | 1.03 Mn |
| Dec 31, 2020 | 1.03 Mn |
| Jun 30, 2020 | 2.61 Mn |
| Mar 31, 2020 | 421,000.00 |
| Dec 31, 2019 | 16.25 Mn |
| Sep 30, 2019 | 57.11 Mn |
| Jun 30, 2019 | 44.36 Mn |
| Mar 31, 2019 | 59.56 Mn |
| Dec 31, 2018 | 86.74 Mn |
| Sep 30, 2018 | 82.46 Mn |
| Jun 30, 2018 | 80.17 Mn |